ATX-GD-59 in Patients With Graves Disease Not Treated With Anti-thyroid Therapy

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

12 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-09-30

Study Completion Date

2018-02-14

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Phase 1 study to assess the safety and biological activity of ATX-GD-59 in patients with Graves Disease not currently treated with anti-thyroid therapy. This will be an open label dose titration involving injections on 10 occasions, each two weeks apart. After dosing is complete there will be a 12 week follow up period. Blood samples will be drawn throughout the study to monitor safety and the body's response to the injections. Thyroid function will be measured throughout the trial to monitor Graves disease progression.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Proof-of-Concept Study to Assess Batoclimab in Participants With Graves' Disease

NCT05907668

Graves Disease

COMPLETED PHASE2

Remission Induction and Sustenance in Graves' Disease 2

NCT00796913

Graves Disease Hyperthyroidism

COMPLETED NA

A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease

NCT07018323

Graves' Disease

RECRUITING PHASE2

Tolerability, Safety and Pharmacokinetics Study of GX-30 in Total Thyroidectomy or Near Total Thyroidectomy Patients

NCT03276988

Total Thyroidectomy Near-total Thyroidectomy

COMPLETED PHASE1/PHASE2

A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease

NCT06727604

Graves' Disease

RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Graves Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ATX-GD-59 treatment

An upward titration over five dose levels (25, 50, 100, 400 and 800 micrograms) followed by 5 doses of 800 micrograms of ATX-GD-59 will be administered two weeks apart by intradermal injection.

Group Type EXPERIMENTAL

ATX-GD-59

Intervention Type BIOLOGICAL

Disease specific immune modulating treatment for Graves Disease

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ATX-GD-59

Disease specific immune modulating treatment for Graves Disease

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. A diagnosis of Graves' disease as assessed by a physician from clinical and laboratory findings and not receiving anti-thyroid therapy.
2. Quantifiable levels of TSHR antibodies.
3. Raised levels of free T3 and/or free T4 (not exceeding 15 pmol/L and 35 pmol/L respectively) including undetectable levels of thyroid stimulating hormone.
4. HLA-DRB1\*15, HLA DRB1\*03 and or HLA DRB1\*04 positive.
5. Age 18 - 65 years inclusive at the time of informed consent.
6. The subject must be willing and able to give written informed consent and must be willing to comply with protocol assessments/procedures.
7. Male subjects must be sterile (biologically or surgically) or commit to the use of a reliable method of birth control for the duration of the study until at least 90 days after the last dose of ATX-GD-59.
8. Female subjects of child bearing potential must: - neither be pregnant nor breast-feeding, nor attempting to conceive, and - use a highly effective method of contraception as defined below, throughout the entire duration of the study and for at least 90 days after the last dose of ATX-GD-59. A serum pregnancy test will be performed at the screening visit in women of child bearing potential. Thereafter urine pregnancy tests will be performed. A positive result will exclude the woman from the study immediately. A highly effective method of contraception is defined as those which result in a low failure rate when used consistently and correctly such as implants, injectable, combined oral contraceptives, some Intrauterine Devices (IUDs), unless post-menopausal or surgically sterilized. Barrier forms of contraception are considered appropriate when used in combination with one of the above methods.

Exclusion Criteria

1. Subjects who are pregnant or breastfeeding and/or subjects in the post-partum period.
2. A known history of, or hypersensitivity reactions that in the opinion of the investigator would exclude the subjects' participation in the study.
3. Treatment with any Anti-Thyroid Drugs eg carbimazole within the previous 3 months prior to Study Day 1.
4. Previous treatment with radioiodine or (partial or complete) thyroidectomy.
5. Signs of moderate or severe orbitopathy including optic nerve compression requiring steroids and/or a clinical activity score \>3.
6. Large and compressive goitres causing localised symptoms such as difficulty swallowing or breathing.
7. Treatment with steroids (administered via the oral and/or parenteral routes) or adrenocorticotropic hormone with the exception of inhaled steroids within the three months prior to Study Day 1.
8. Symptoms and signs of thyroid storm such as confusion, pyrexia with no other cause than hyperthyroidism.
9. Significant cardiac disease and/or atrial fibrillation that would require urgent treatment of thyrotoxicosis.
10. Prior treatment with biological or peptide-based therapeutics including rituximab.
11. Prior use of disease related T cell vaccine or peptide-tolerising agent to treat Graves' disease.
12. Detectable levels of antibodies in plasma specific for any of the peptides within ATX-GD-59 at the screening visit.
13. A history of significant drug allergies.
14. The use of any investigational drug, or participation in any Clinical Trial within three months prior to Study Day 1.
15. Treatment with any cytokine or anti-cytokine therapy within three months prior to Study Day 1.
16. Inadequate liver function, defined by a total bilirubin, aspartate aminotransferase (AST), alanine aminotransferase (ALT) or alkaline phosphatase \> 3 times the upper limit of the normal values at Screening visit. 17. Subject with any significant medical illness or psychiatric condition that in the opinion of the Investigator, would preclude participation in the study or impair the ability to give informed consent; any other clinically apparent autoimmune disease.

18\. Clinically significant illness, as determined by the investigator, within 4 weeks prior to the first dose (Study Day 1) of ATX-GD-59.

19\. Known history of active or chronic infectious disease or any disease which compromises immune function (e.g. HIV+, HTLV-1, Lyme disease, Latent or active TB, Hepatitis).

20\. Major surgery in previous four weeks before screening visit. 21. Known osteoporosis or metabolic bone disease.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No